TP 252

Drug Profile

TP 252

Alternative Names: Eicosapentaenoic acid free fatty acid derivative - Thetis; EPA free fatty acid derivative - Thetis; EPA-FFA derivative - Thetis

Latest Information Update: 12 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Thetis Pharmaceuticals
  • Class Antineoplastics; Eicosanoids; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Familial adenomatous polyposis

Most Recent Events

  • 06 May 2017 Pharmacodynamics and pharmacokinetics data from a preclinical study in Familial adenomatous polyposis presented at the Digestive Disease Week (DDW - 2017)
  • 27 Jan 2016 Thetis Pharmaceuticals has patent protection for TP 252 in USA
  • 19 Jan 2016 TP 252 receives Orphan Drug status for Familial adenomatous polyposis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top